281-300 of 354 results by Mike Winters

Previous  |  1 |  ... |  10 |  11 |  12 |  13 |  14 |  15 |  16 |  17 |  18 |  Next

Title: Intraabdominal Hypertension

Category: Critical Care

Keywords: intraabdominal pressure, intraabdominal hypertension, bladder pressure (PubMed Search)

Posted: 9/8/2008 by Mike Winters, MBA, MD (Updated: 3/5/2026)

Intraabdominal Hypertension and the Critically Ill

Show References



Title: Bicarbonate for lactic acidosis from shock?

Category: Critical Care

Keywords: sodium bicarbonate, lactic acidosis, hypoperfusion, shock (PubMed Search)

Posted: 9/3/2008 by Mike Winters, MBA, MD (Updated: 3/5/2026)

Bicarbonate for severe lactic acidosis from shock?

 

 

 

 

 

 

 

 

 

Show References



Title: Vasopressor extravasation

Category: Critical Care

Keywords: norepinephrine, epinephrine, epinephrine, dopamine, phentolamine (PubMed Search)

Posted: 8/26/2008 by Mike Winters, MBA, MD (Updated: 3/5/2026)

 Phentolamine for vasopressor extravasation

I was recently informed of a case from an another institution in which a patient was started on a vasopressor medication via a peripheral IV while attempts at central access where attempted.  The patient unfortunately suffered permanent extremity ischemia due to significant extravasation of the vasopressor medication into the soft tissue.

 



Title: PEEP in nonhypoxemic respiratory failure

Category: Critical Care

Keywords: PEEP, respiratory failure, ventilator associated pneumonia (PubMed Search)

Posted: 8/19/2008 by Mike Winters, MBA, MD (Updated: 3/5/2026)

 

PEEP in Nonhypoxemic Respiratory Failure

Show References



Title: Pressure Regulated Volume Control

Category: Critical Care

Keywords: PRVC, pressure control, volume control, ventilator-induced lung injury (PubMed Search)

Posted: 8/12/2008 by Mike Winters, MBA, MD (Updated: 3/5/2026)

Pressure Regulated Volume Control (PRVC)



Title: DOPE

Category: Critical Care

Keywords: post-intubation hypoxia, pneumothorax, mechanical ventilation (PubMed Search)

Posted: 8/5/2008 by Mike Winters, MBA, MD (Updated: 3/5/2026)

Post-intubation deterioration?  Remember DOPE



Title: Plateau Pressure

Category: Critical Care

Keywords: acute lung injury, alveolar overdistention, plateau pressure (PubMed Search)

Posted: 7/29/2008 by Mike Winters, MBA, MD (Updated: 3/5/2026)

The Importance of Plateau Pressure

Show References



Title: Asthma and Mechanical Ventilation

Category: Critical Care

Keywords: asthma, mechanical ventilation, hyperinflation (PubMed Search)

Posted: 7/22/2008 by Mike Winters, MBA, MD (Updated: 3/5/2026)

Mechanical Ventilation in Asthma

Show References



Title: Noninvasive Ventilation Pearls

Category: Critical Care

Keywords: noninvasive ventilation (PubMed Search)

Posted: 7/15/2008 by Mike Winters, MBA, MD (Updated: 3/5/2026)

 Noninvasive Ventilation Pearls

Show References



Title: Redefining Hypotension

Category: Critical Care

Keywords: hypotension, trauma, elderly (PubMed Search)

Posted: 7/8/2008 by Mike Winters, MBA, MD (Updated: 3/5/2026)

Hypotension begins at 110 mmHg?

Show References



Title: Etomidate and adrenal suppression

Category: Critical Care Literature Update

Keywords: etomidate, adrenal insufficiency (PubMed Search)

Posted: 7/7/2008 by Mike Winters, MBA, MD (Updated: 3/5/2026)

Recent Articles from the Critical Care Literature

Duration of adrenal insufficiency following a single dose of etomidate in critically ill patients

Vinclair M, Broux C, Faure P, Brun J, Genty C, et al. Intensive Care Med 2008;34:714-9.
            Etomidate has become a favored first-line induction agent for intubation in the emergency department.  Given its excellent hemodynamic tolerance, etomidate is especially useful in hemodynamically unstable patients. A known side effect of etomidate is adrenal suppression, due to inhibition of 11β-hydroxylase, the enzyme that converts 11β-deoxycortisol into cortisol. As a result, recent literature has raised concerns that etomidate may worsen patient outcomes in those with relative adrenal insufficiency, namely those with septic shock.
            The current study is a prospective, observational study conducted in France from October 2005 to January 2006. The purpose of the study was to assess the duration of adrenal suppression following a single dose of etomidate, given either in the field or in the emergency department for RSI. Importantly, patients with septic shock, or those with preexisting adrenal insufficiency, were excluded from this study. To diagnose adrenal insufficiency, the investigators measured total cortisol and 11β-deoxycortisol following a high-dose cosyntropin stimulation test (250 mcg). Values were obtained at 12, 24, 48, and 72 hours following etomidate administration. An accumulation of 11β-deoxycortisol with a lack of cortisol rise was used to establish etomidate-related adrenal insufficiency.
            A total of 40 patients were included in this study. The majority of patients required intubation as a result of either trauma or subarachnoid hemorrhage. At hour 12, 80% of patients fulfilled the investigators definition of etomidate-related adrenal insufficiency, whereas by hour 48, only 9% met criteria. In addition, at hour 24, patients with etomidate-related adrenal suppression required larger doses of norepinephrine that those without adrenal inhibition. From their data, the authors conclude that a significant proportion of patients without septic shock have adrenal suppression for at least 12 hours following a single dose of etomidate. This effect, however, appeared reversible in that most patients recovered adrenal function by hour 48. Finally, the authors recommend that systemic steroid supplementation be considered during the first 48 hours in hemodynamically unstable patients who have received etomidate for intubation.
            There are a number of limitations with this study. The most important limitation is, perhaps, the authors’ definition of etomidate-related adrenal insufficiency. Diagnosing adrenal insufficiency in critically ill patients remains controversial. The cosyntropin test (high- or low-dose) has many recognized limitations. In addition, measurement of 11β-deoxycortisol is difficult because reference values for critically ill patients are rare. The authors also chose to measure total serum cortisol, rather than the more biologically active free serum cortisol. Lastly, data for all 40 patients at 72 hours was not complete.
            Take Home Points: This small, observational study found a high incidence of adrenal suppression for at least the first 12 hours in unstable patients receiving etomidate for intubation. Importantly, this study excluded patients with sepsis or septic shock. Given the limited number of patients and the difficulty in defining adrenal insufficiency in the critically ill, this study provides some interesting results and is hypothesis-generating at best. Their recommendation for systemic steroid supplementation during the first 48 hours following etomidate administration in unstable patients cannot be supported by this study.


Title: recombinant Factor VIIa for ICH

Category: Critical Care Literature Update

Keywords: intracerebral hemorrhage, recombinant factor VIIa (PubMed Search)

Posted: 7/6/2008 by Mike Winters, MBA, MD (Updated: 3/5/2026)

 

Recent Articles from the Critical Care Literature

Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage.

Mayer SA, Brun NC, Begtrup MSc, Broderick J, Davis S, et al. NEJM 2008;358:2127-37.
            Intracerebral hemorrhage (ICH) accounts for approximately 10% to 15% of all strokes, yet has the highest morbidity and mortality, with up to 40% of patients dying within 30 days. Aside from age, size, location, intraventricular extension, and GCS, hematoma expansion is an independent determinant of morbidity and mortality. Hematoma expansion is reported to occur in up to 70% of patients within the first several hours of the ICH. Recent research has focused on therapies to limit hematoma expansion. One such therapy is recombinant human activated Factor VII (rFVIIa). Excitement regarding this expensive drug came from a single phase 2 trial (Mayer SA, et al. NEJM 2005:352:777-85.) that demonstrated rFVIIa significantly reduced hematoma expansion and improved patient mortality.
            The FAST trial (Factor Seven for Acute Hemorrhagic Stroke), was a manufacture sponsored, phase 3 trial performed by the same investigators to confirm the findings of their previous phase 2 study. The FAST trial was a multi-center, randomized, double-blind, placebo-controlled trial conducted at 122 sites in 22 countries. Patients had to be at least 18 years of age with a spontaneous ICH documented by CT within 3 hours of symptom onset. Important exclusion criteria included GCS < 5 at presentation, secondary ICH (trauma, AVM), current anticoagulant therapy, thrombocytopenia, DIC, previous disability from CVA, or a thromboembolic event < 30 days prior to symptom onset. The primary end-point was disability or death defined by a modified Rankin score of 5 or 6 at day 90. The modified Rankin score evaluates global disability and handicap and ranges from 0 to 6. A score of 5 indicates a patient who is bed-bound and incontinent, whereas a score of 6 indicates death.
            Of 8,886 patients screened, 821 underwent randomization and received placebo, 20 mcg/kg of rFVIIa, or 80 mcg/kg of rFVIIa. Treatment had to start within 1 hour of the baseline CT and no more than 4 hours after the onset of symptoms. Patients then underwent a repeat CT at 24 hours and 72 hours to evaluate for hematoma expansion. Of note, the majority of the patients in this study were Caucasian males, older than 65 year of age who had deep gray matter ICHs. 
            As reported by the trial investigators, rFVIIa did reduce hematoma expansion at 24 hours compared to placebo. In the placebo arm, 26% of patients had hematoma growth, whereas only 11% of patients who received 80 mcg/kg of rFVIIa had hematoma expansion. In addition, the investigators report that the reduction in hematoma growth was even greater in those treated in less than 2 hours from onset of symptoms. However, when you look at the data for 72 hours, there was no significant difference in total hematoma volume or edema volume. More importantly, mortality at 90 days did not differ between placebo and the treatment groups. In fact, a higher percentage of patients who received 80 mcg/kg of rFVIIa had a worse outcome than compared with placebo. Furthermore, there was an absolute increase of 5% in the frequency of arterial thromboembolic serious events (MI, ischemia CVA) in the group receiving 80 mcg/kg of rFVIIa.
            Take Home Point: This phase 3 trial failed to demonstrate improved 90 day mortality in patients with spontaneous ICH who received rFVIIa. Although hematoma expansion was reduced at 24 hours in the rFVIIa groups, total lesion volume and edema volume at 72 hours remained unchanged. Although rFVIIa has been used in a variety of clinical settings, the results of this study indicate that it does improve mortality in patients with spontaneous ICH. Given the expense of the drug and lack of benefit, this should not be a drug we are using in the ED to treat patients with spontaneous ICH.


Title: Diabetes and Osteomyelitis

Category: Infectious Disease

Keywords: diabetes, osteomyelitis, temperature, white blood cell count (PubMed Search)

Posted: 7/1/2008 by Mike Winters, MBA, MD (Updated: 3/5/2026)

Does this Patient with Diabetes have Osteomyelitis?

Show References



Title: Passive Leg Raising

Category: Critical Care

Keywords: passive leg raising, fluid responsiveness (PubMed Search)

Posted: 6/17/2008 by Mike Winters, MBA, MD (Updated: 3/5/2026)

Passive Leg Raising (PLR)

Show References



Title: Acinetobacter

Category: Critical Care

Keywords: acinetobacter, polymixin, ventilator-associated pneumonia, bacteremia (PubMed Search)

Posted: 6/3/2008 by Mike Winters, MBA, MD (Updated: 3/5/2026)

Acinetobacter in the Critically Ill

Show References



Title: Fluids and Acute Liver Failure

Category: Critical Care

Keywords: jlactated Ringer's solution, dextrose, cerebral edema (PubMed Search)

Posted: 5/27/2008 by Mike Winters, MBA, MD (Updated: 3/5/2026)

Fluids in Acute Liver Failure

Show References



Title: COPD and mechanical ventilation

Category: Critical Care

Keywords: bicarbonate, pH, COPD, mechanical ventilation (PubMed Search)

Posted: 5/20/2008 by Mike Winters, MBA, MD (Updated: 3/5/2026)

COPD and mechanical ventilation

Show References



Title: PEEP in Acute Lung Injury

Category: Critical Care

Keywords: PEEP, acute lung injury, acute respiratory distress syndrome (PubMed Search)

Posted: 5/13/2008 by Mike Winters, MBA, MD (Updated: 3/5/2026)

Acute Lung Injury (ALI) / Acute Respiratory Distress Syndrome (ARDS)



Title: Propofol Infusion Syndrome

Category: Critical Care

Keywords: propofol (PubMed Search)

Posted: 5/7/2008 by Mike Winters, MBA, MD (Updated: 3/5/2026)

Propofol Infusion Syndrome

Show References



Title: Intra-aortic balloon pump counterpulsation

Category: Critical Care

Keywords: intra-aortic balloon pump counterpulsation, cardiogenic shock (PubMed Search)

Posted: 4/29/2008 by Mike Winters, MBA, MD (Updated: 3/5/2026)

Intra-aortic balloon pump counterpulsation

Show References



Previous  |  1 |  ... |  10 |  11 |  12 |  13 |  14 |  15 |  16 |  17 |  18 |  Next